+ +

•  

   

     Western blot analysis of MRP1 expression in A431 cell lysate.    

  
  

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

The multidrug resistance-associated protein 1 (MRP1), encoded by the ABCC1 gene, is a member of the ATP-binding cassette (ABC) transporter family. First identified in 1992. MRP1 is renowned for its role in multidrug resistance (MDR) in cancer therapy. Unlike P-glycoprotein (P-gp), another ABC transporter linked to MDR, MRP1 primarily exports organic anions, including glutathione-, glucuronate-, or sulfate-conjugated compounds, and certain chemotherapeutic agents (e.g., anthracyclines, vinca alkaloids). It is broadly expressed in normal tissues, such as the lungs, kidneys, testes, and placenta, where it participates in detoxification, inflammation regulation, and endogenous metabolite transport.

In cancer, MRP1 overexpression contributes to chemotherapy failure by extruding drugs from malignant cells, reducing intracellular concentrations. Its involvement extends beyond oncology; MRP1 dysfunction is implicated in cardiovascular diseases, neurological disorders, and cystic fibrosis. MRP1 antibodies are essential tools for detecting protein expression in research and diagnostics, aiding in studies of drug resistance mechanisms, tissue distribution, and therapeutic targeting. Monoclonal and polyclonal antibodies against MRP1 are widely used in techniques like Western blotting, immunohistochemistry, and flow cytometry. Recent efforts focus on developing MRP1 inhibitors to overcome MDR, with antibodies playing a pivotal role in validating inhibitor efficacy and mechanistic studies.